Thermo Fisher expands into Switzerland as part of CSL collaboration
Just days after Thermo Fisher Scientific prepped to expand a St. Louis plant, the company announced it’s taking over a new, 1.5 million-square-foot site in Switzerland with plans to add 200 new employees.
The move is a part of a May 2020 partnership with CSL and the site, slated to be completed by next year, will first be used to manufacture CSL’s recombinant factor IX product Idelvion, a treatment for hemophilia B, with more treatments to be made there in the future.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.